Protara Therapeutics, Inc. Interest Income (Expense), Net
Protara Therapeutics, Inc. (TARA) reported Interest Income (Expense), Net of $1.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2026-08-11
- Protara Therapeutics, Inc. interest income (expense), net for the quarter ending 2026-06-30 was $1.48M, a 21.01% increase year-over-year.
- Protara Therapeutics, Inc. interest income (expense), net for the quarter ending 2025-06-30 was $1.22M.
- Protara Therapeutics, Inc. interest income (expense), net for the quarter ending 2021-09-30 was $53.00K, a 42.39% decline year-over-year.
- Protara Therapeutics, Inc. interest income (expense), net for the quarter ending 2021-06-30 was $10.00K, a 92.06% decline year-over-year.
- Protara Therapeutics, Inc. interest income (expense), net for fiscal 2020 was -$34.00K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 3 month as first filed | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 6 month as first filed | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 9 month as first filed | Interest Income (Expense), Net 12 month | Interest Income (Expense), Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.48M 10-Q · filed 2026-08-11 | $3.14M 10-Q · filed 2026-08-11 | ||||||
| 2025-06-30 | $1.22M 10-Q · filed 2026-08-11 | $2.78M 10-Q · filed 2026-08-11 | ||||||
| 2021-09-30 | $53.00K 10-Q · filed 2021-11-04 | $63.00K derived: sum of 2 quarters · filed 2021-11-04 | $178.00K 10-Q · filed 2021-11-04 | -$173.00K derived: sum of 4 quarters · filed 2022-03-09 | ||||
| 2021-06-30 | $10.00K 10-Q · filed 2021-08-05 | $125.00K 10-Q · filed 2021-08-05 | -$226.00K derived: sum of 3 quarters · filed 2022-03-09 | -$134.00K derived: sum of 4 quarters · filed 2022-03-09 | ||||
| 2021-03-31 | $115.00K 10-Q · filed 2021-05-06 | -$236.00K derived: sum of 2 quarters · filed 2022-03-09 | -$144.00K derived: sum of 3 quarters · filed 2022-03-09 | -$18.00K derived: sum of 4 quarters · filed 2022-03-09 | ||||
| 2020-12-31 | -$351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$259.00K derived: sum of 2 quarters · filed 2022-03-09 | -$133.00K derived: sum of 3 quarters · filed 2022-03-09 | -$34.00K 10-K · filed 2022-03-09 | $466.00K 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $92.00K 10-Q · filed 2021-11-04 | $92.09K 10-Q · filed 2020-11-12 | $218.00K derived: sum of 2 quarters · filed 2021-11-04 | $317.00K 10-Q · filed 2021-11-04 | $317.31K 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $126.00K 10-Q · filed 2021-08-05 | $125.84K 10-Q · filed 2020-07-31 | $225.00K 10-Q · filed 2021-08-05 | $225.21K 10-Q · filed 2020-07-31 | ||||
| 2020-03-31 | $100.00K 10-Q · filed 2021-05-06 | $99.37K 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |